Home
About Us
Management
Technology & Products
Electroceuticals®
EFFECT Trial
SofPulse® Electroceutical® Therapy
Scientific Studies
Patents
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Home
About Us
Management
Technology & Products
Electroceuticals®
EFFECT Trial
SofPulse® Electroceutical® Therapy
Scientific Studies
Patents
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Management
Kodenbushi
Investors
Overview
News / Events
Press Releases
Email Alerts
Company Information
Profile
Management Team
Scientific Advisory Board
Presentations
IR Contacts
FAQ
Financial Information
Quarterly Results
Stock Data
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Email Alerts
Presentations
Tear Sheet
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2020
2019
2018
2017
2016
2015
2014
2013
2012
Jun 29, 2017 • 8:30 AM EDT
Endonovo Therapeutics Issues Open Letter and Update to Its Shareholders
Jun 1, 2017 • 8:00 AM EDT
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Kidney Disease
May 11, 2017 • 9:00 AM EDT
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)
May 4, 2017 • 12:51 PM EDT
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device for Treatment of Critical Limb Ischemia
Mar 23, 2017 • 9:29 AM EDT
Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology
Dec 19, 2016 • 9:00 AM EST
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Nov 28, 2016 • 12:29 PM EST
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Nov 7, 2016 • 9:05 AM EST
Endonovo Therapeutics (ENDV): Targeting $20+ Billion Market for In Vitro ADME and Toxicology Testing
Oct 18, 2016 • 7:05 AM EDT
Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective
Oct 14, 2016 • 6:50 AM EDT
Endonovo Therapeutics Issues Corporate Update
<< Previous
1...
3
4
5
6
7
8
9
10
11
12
Next >>
Show All